lutetium ethylenediaminetetramethylene phosphonic acid

03/01/2014 - "(177)Lu-EDTMP, with only low bone marrow toxicity, provided significant pain relief to patients and considerably increased their mobility, resulting in an overall improvement in the quality of life. "
05/01/2015 - "(177)Lu-EDTMP in the form of sterile slow IV injection was administered with a dose of 29.6 MBq/kg. Short form of brief pain inventory questionnaire was used to evaluate the efficiency of the intervention. "
04/01/2015 - "The results showed that (177)Lu-ZLD has better characteristics compared to (177)Lu-EDTMP and can be a good candidate for bone pain palliation. "
01/01/2015 - "The secondary objective was to compare low-dose and high-dose (177)Lu-EDTMP in bone pain palliation. "
03/01/2014 - "The potential of (177)Lu-EDTMP for palliation of metastatic bone pain has been documented in the recent literature. "

02/01/2013 - "This study indicated that (177)Lu-EDTMP was an effective and safe treatment for palliation of metastatic bone pain in patients with prostate or breast cancer. "
01/01/2015 - "(177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study."
01/01/2015 - "(177)Lu-EDTMP was found to be a safe and effective radiopharmaceutical for bone pain palliation in patients with metastatic prostate and breast carcinoma. "
01/01/2015 - "The purpose of this study was to evaluate the efficacy and safety of (177)Lu-EDTMP for pain palliation in patients with bone metastases from castration-resistant prostate and breast cancer. "
02/01/2013 - "In this phase II study, we assessed the efficacy and safety of (177)Lu-EDTMP for bone pain palliation in patients with breast cancer and hormone refractory prostate cancer with bone metastases. "

10/01/2021 - "The results demonstrated higher uptake of [177Lu]Lu-EDTMP in bone metastases compared to normal bones. "
10/01/2021 - "Prospective evaluation of organ-specific dose and lesional doses following therapeutic [177Lu]Lu-EDTMP administration in patients with multiple skeletal metastases and its correlation with clinical hematological toxicity."
03/01/2014 - "Ten patients (median age, 68.5 y) with disseminated skeletal metastases received a single bolus infusion of (177)Lu-EDTMP (3.7 GBq). "
08/01/2016 - "In this regard, we present a case of cocktail therapy applied using Lu-PSMA-617 and Lu-EDTMP therapy in a 38-year-old male CRPC patient with both soft tissue and extensive skeletal metastases. "
05/01/2015 - "(177)Lu-EDTMP has shown suitable physical and biological properties with good results in long term bone pain relief for patients with bone metastasis. "

12/01/2014 - "Freeze-dried EDTMP kits, suitable for the preparation of patient doses of (177)Lu-EDTMP, have been developed and used in preliminary studies for treating the cancer patients with disseminated skeletal metastases. "
10/01/2014 - "Radiolabeled (177)Lu-EDTMP (Ethylenediamine tetramethylene phosphonic acid) is by and large used for bone pain palliation in cancer patients. "

10/01/2014 - "Camptothecin Enhances Cell Death Induced by (177)Lu-EDTMP in Osteosarcoma Cells."
10/01/2014 - "In vitro cell studies are carried out in osteosarcoma cells MG-63 to evaluate the combined effect of anticancer drug camptothecin (CPT) and (177)Lu-EDTMP. "